Hospitals sidestep leasing despite credit crunch
Results of a survey of hospital-based radiology practice directors suggest the credit crunch that has accompanied the national recession does not appear to have promoted interest among hospital administrators in leasing as an option for obtaining new medical equipment.
Results of a survey of hospital-based radiology practice directors suggest the credit crunch that has accompanied the national recession does not appear to have promoted interest among hospital administrators in leasing as an option for obtaining new medical equipment.
According to the MarkeTech Group, which conducted the survey in June at the request of Diagnostic Imaging, more than half of 186 hospital-based radiology administrators responding to the survey said they were not at all or somewhat interested in leasing. More than a third said the bond market downturn would have no impact on their ability to finance projects and equipment purchases.
“The hospital market is very entrenched in a capital acquisition mentality,” said MarkeTech Group CEO Christian Renaudin, Ph.D. “They want to own their own equipment.”
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
